VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development ...

RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization, today announced a strategic partnership with BlueRock Therapeutics, a leader in stem cell therapeutic ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Gene therapies offer incredible promise for treating diseases with a genetic component. Several gene therapies are already available, and adeno-associated virus (AAV) has become a popular choice for ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

We spoke to developer of the HEK293 cell line, Frank Graham, about the challenges faced and serendipity required to pioneer a ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

To date, more than 100 clinical trials with human pluripotent stem cell (hPSC)-derived products have been initiated worldwide and an increasing number of potential hPSC-derived clinical products have ...

Danish researchers have created new cell lines that need a less tailored feeding schedule and produce fewer waste products. The team, from the Technical University of Denmark (DTU), says they’ve ...

Gross SC-islet morphology and size were maintained, yet the fraction of NKX6.1-positive β cells fell substantially, pointing ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...